known effects on red blood cells and thrombocytes as Introduction well. In renal transplant recipients we replaced CsA therapy by MMF in an attempt to reduce the immunoClinical trials in kidney transplant recipients have suppressive load 1 year after kidney transplantation.
shown a higher efficacy of mycophenolate mofetil During this study we observed the effect of MMF on (MMF ) and prednisone (Pred ) compared to azathiohaematological parameters such as haemoglobin (Hb), prine (AZA) and Pred to prevent acute rejection leukocytes, and thrombocytes.
[1-3]. Both MMF and AZA act on purine synthesis, Methods. One year after kidney transplantation 26 aiming to decrease the proliferative response of allostable patients were converted from cyclosporin A stimulated lymphocytes [4] [5] [6] [7] . AZA and its metabolite (CsA) to MMF (2 g/day). Thereafter, these patients 6-mercaptopurine (6-MP) act in a non-selective were tapered twice in their MMF dose from 2 g to manner [4] [5] [6] , and may cause pancytopenia. MMF, 1.5 g (4 months after conversion) and from 1.5 to 1 g however, is a specific inhibitor of inosine monophos-(8 months after conversion) per day. The Hb levels, phate dehydrogenase (IMPDH ), a key enzyme in the leukocyte and thrombocyte counts, and mycophenolic purine synthesis of lymphocytes [7] , and should theoracid (MPA) trough levels were routinely measured.
etically have no or minimal effect on erythrocyte and Results. After conversion from CsA to MMF not only thrombocyte proliferation. creatinine levels and the number of leukocytes, but During a conversion trial in renal transplant also the haemoglobin (Hb) level significantly decreased patients, we investigated the effect of conversion from in 21/26 patients (P=0.0004). In eight patients the Hb cyclosporin A (CsA) to MMF on leukocytes, thrombolevel dropped more than 1 mmol/l (=1.61 g/dl ). Only cytes, haemoglobin (Hb), and serum creatinine. In in two of eight patients was an explanation for blood addition we studied the correlation between mycoloss found. The effect on Hb level did not ameliorate phenolic acid (MPA) trough levels and the observed after the first MMF dose reduction to 1.5 g/day. After haematological side-effects. MPA is the active immunotapering the MMF dose to 1 g/day, the Hb approached suppressive metabolite of MMF and is formed followthe pre-conversion level. Not only the MMF dose but ing oral administration of MMF [8] . also the mycophenolic acid (MPA) trough level correlated with the Hb level.
Conclusions.
After conversion from CsA to MMF 1 Subjects and methods year after kidney transplantation, a decrease in Hb level and leukocyte count was observed. The MPA Patients transplanted between September 1995 and January trough level correlated also with the Hb level. The 1997, with stable graft function and on maintenance treateffect on the Hb level was reversible after dose reduc-ment of CsA (±150 ng/ml CsA trough level ) and Pred tion. This finding suggests that MMF exerts a negative (10 mg/day) were converted to MMF (2 g/day) and Pred effect on erythropoietic cells.
(10 mg/day) 1 year after kidney transplantation. In week 53 MMF treatment was started, while over a subsequent timeperiod of 4 weeks CsA was withdrawn. Four and 8 months We report on 26 patients (12 male, 14 female; 6/14 females remained stable (median CsA, ; 2 g premenopausal ) converted to MMF and reaching this low-MMF, 222 (147-494); 1.5 g MMF, 222 (148-401); dose maintenance immunosuppression without acute rejec-1 g MMF, 222×109/l (128-295)). Thrombocytopenia tions, and observed the leukocyte and thrombocyte count (thrombocytes <120×109/l ) never occurred after conin peripheral blood and the Hb level over time. In addi-version to MMF. tion, fasting plasma MPA trough levels were measured A significant decrease in the Hb level was found in (range 0-15 mg/ml, inter-and intra-assay coefficient of 21/26 patients after conversion from CsA to MMF variation ∏5%) (EMIT-Mycophenolic Acid Assay, Behring (median of total group, from 8.3 to 7.9 mmol/l Diagnostics Inc. San Jose, CA, USA).
(=from 13.4 to 12.7 g/dl ); P=0.0004) ( Figure 1B <7.5 mmol/l (=12.1 g/dl )). In five of these patients the drop in Hb was more than 1 mmol/l (=1.61 g/dl ) and in three other patients this effect was also observed.
Results
Accordingly, in eight of 26 patients (31%) the decrease in Hb was more than 1 mmol/l (=1.61 g/dl ). Only in After conversion from CsA to MMF (2 g/day) the two cases was an explanation for the drop in Hb level median creatinine level of the total group decreased found. In both cases the anaemia was caused by from 125 mmol/l (range 80-225) to 112 (68-247) (P= menometrorrhagia, which was treated with iron 0.0009). Tapering the MMF dose to 1.0 g/day did not supplementation and hormonal therapy. Haemolysis lead to a further change in the creatinine concentration, and significant faecal blood loss did not occur, and resulting in a median creatinine level of 113 (71-228) none of these patients needed a blood transfusion. The mmol/l at the end of the observation period.
first dose reduction of MMF to 1.5 g did not positively After conversion from CsA to MMF the number of influence the Hb level (P=0.12). After the second dose leukocytes decreased in 17/26 patients (median of total reduction to 1 g MMF, the Hb level in 20/26 patients group: from 9.5 to 8.1×109/l ) (P=0.04) ( Figure 1A ). was higher than the levels determined during 2 g MMF These counts did not change after the MMF dose treatment, consequently the Hb levels reached the reductions to 1.5 g and 1 g. Consequently, the leuko-levels of pre-conversion (P=0.75). cyte counts measured during 1 g/day MMF were still
We wondered whether not only the dose of MMF, lower in 21/26 patients compared to the counts during but also the MPA trough levels were correlated with CsA therapy (median of total group: 8.5 vs 9.5×109/l; these side-effects of MMF. The MPA level was not P=0.01). However, significant leukopenia ( leukocytes correlated with the leukocyte counts (Spearman r= <4×109/l ) did not develop.
−0.13, P=0.27) (Figure 2A) , while the MPA level After conversion from CsA to MMF and subsequent was negatively correlated with the Hb level (r=−0.35, P=0.002) ( Figure 2B ). In addition, we found a signi-MMF dose reductions, the thrombocyte counts 
Discussion
of thrombocytopenia: with thrombocytopenia in 3.1% ( European) and 5% ( Tricontinental ) of the patients treated with 3 g MMF compared to 4.2% ( European) The occurrence of haematological side-effects described and 9% ( Tricontinental ) of the patients treated with using MMF in renal transplant patients seems to be dose dependent [3, 9] . The 'European Mycophenolate 2 g MMF/day [3, 9] . Mofetil Cooperative Study Group' reported that leukoHowever, it should be noted that these patients were penia occurred in 13.8% of the patients receiving treated with MMF, CsA, and Pred within the first year after kidney transplantation. The first months after transplantation are well known for the incidence of various infections e.g. cytomegalovirus (CMV ) which may have caused a considerable number of episodes of thrombocytopenia and/or leukopenia. Our patients were converted from CsA to MMF 1 year after transplantation, and CMV disease or other infections are no longer a problem at this juncture. Additionally, apart from the conversion from immunosuppression other drug treatment was unchanged. The 'European Mycophenolate Mofetil Cooperative Study Group' reported that 6.8% of the patients from the group treated with a daily dose of 3 g MMF developed anaemia. This percentage was 4.2% when patients were treated with 2 g MMF [9] . In the 'Tricontinental Mycophenolate Mofetil Renal Transplant Study Group' these percentages were 15 and 9% respectively [3] . However, no definition of anaemia was given.
In our series, in six of 26 patients (23%) the Hb level dropped with more than 1 mmol/l (=1.61 g/dl ), while in 15 other patients the Hb level also decreased. Giving MMF in combination with CsA within the first 
